Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481127 | 0.95 | MRGPRX4 (0.56) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL481209 | 0.89 | MAPT (0.70) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL481243 | 0.89 | MRGPRX4 (0.55) | MAPTSMN1; SMN2MRGPRX4FOLH1 | |
| SCHEMBL16242903 | 0.84 | MAPT (0.75) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL481253 | 0.84 | MAPT (0.48) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL481630 | 0.84 | MAPT (0.68) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL481051 | 0.83 | MRGPRX4 (0.50) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL481164 | 0.81 | MAPT (0.67) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| Hydrochloric Acid SCHEMBL12231455 | 0.79 | MAPT (0.55) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL17176199 | 0.78 | MRGPRX4 (0.54) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2441762-A1 | Potentiators of Glutamate Receptors | Eli Lilly and Company (US) | 2012-04-18 | — | — | EP | disclosed |
| EP-2441762-A1 | Potentiators of Glutamate Receptors | Eli Lilly and Company (US) | 2012-04-18 | — | — | EP | disclosed |
| EP-1817301-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7816523-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816523-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816523-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7803938-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803938-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803938-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2006057870-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | GRM1, GRIN1, GRM2 | MAPT 3525/4885CYP2C9 890/4885CYP2C19 693/4885 |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | MAPT 2945/4885CYP2C9 1387/4885CYP2C19 1042/4885 |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | MAPT 2945/4885CYP2C9 1387/4885CYP2C19 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.